ATE333465T1 - Methoden und mittel zur hemmung der cdk4- aktivität - Google Patents

Methoden und mittel zur hemmung der cdk4- aktivität

Info

Publication number
ATE333465T1
ATE333465T1 AT97920857T AT97920857T ATE333465T1 AT E333465 T1 ATE333465 T1 AT E333465T1 AT 97920857 T AT97920857 T AT 97920857T AT 97920857 T AT97920857 T AT 97920857T AT E333465 T1 ATE333465 T1 AT E333465T1
Authority
AT
Austria
Prior art keywords
cdk4
activity
methods
sup
cdk4 activity
Prior art date
Application number
AT97920857T
Other languages
German (de)
English (en)
Inventor
Kathryn L Ball
David P Lane
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE333465T1 publication Critical patent/ATE333465T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97920857T 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4- aktivität ATE333465T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE333465T1 true ATE333465T1 (de) 2006-08-15

Family

ID=26309279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920857T ATE333465T1 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4- aktivität

Country Status (7)

Country Link
US (3) US6962792B1 (cg-RX-API-DMAC7.html)
EP (1) EP0898580B9 (cg-RX-API-DMAC7.html)
JP (1) JP4205165B2 (cg-RX-API-DMAC7.html)
AT (1) ATE333465T1 (cg-RX-API-DMAC7.html)
AU (1) AU2707797A (cg-RX-API-DMAC7.html)
DE (2) DE69736351T4 (cg-RX-API-DMAC7.html)
WO (1) WO1997042222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962792B1 (en) 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
WO1999042834A2 (en) * 1998-02-18 1999-08-26 Theryte Limited Treating cancer
BR9907965A (pt) * 1998-03-23 2000-12-12 Du Pont Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
EP1140202A1 (en) * 1998-12-24 2001-10-10 Ucb S.A. Peptidic product, process and composition
AU4203300A (en) * 1999-04-07 2000-10-23 E.I. Du Pont De Nemours And Company Cell cycle genes in plants
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
CA2494236A1 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. Csnk1gs as modifiers of the p21 pathway and methods of use
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
US20080026992A1 (en) * 2003-10-20 2008-01-31 Ludger Hengst Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
AU2004285745A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
EP1909811B1 (en) * 2005-06-29 2012-02-01 St. George's Enterprises Limited Hox peptides as pbx modulators for the treatment of cancer
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
CA3096978A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
WO2020055758A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
PT665886E (pt) 1992-10-16 2003-10-31 Cold Spring Harbor Lab Rearranjo de complexos de ciclina e suas utilizacoes
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
JP3822232B2 (ja) 1993-08-30 2006-09-13 ベイラー・カレッジ・オブ・メディシン 老化細胞由来ｄｎａ合成阻害因子
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
AU2644495A (en) 1994-05-24 1995-12-18 Baylor College Of Medicine Mimetics of senescent cell derived inhibitors of dna synthesis
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
WO1997003681A1 (en) 1995-07-20 1997-02-06 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
US6962792B1 (en) 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity

Also Published As

Publication number Publication date
EP0898580A1 (en) 1999-03-03
JP2000513805A (ja) 2000-10-17
EP0898580B1 (en) 2006-07-19
WO1997042222A1 (en) 1997-11-13
US6962792B1 (en) 2005-11-08
US20080249025A1 (en) 2008-10-09
DE69736351T2 (de) 2007-07-12
AU2707797A (en) 1997-11-26
DE69736351D1 (de) 2006-08-31
EP0898580B3 (en) 2008-10-29
JP4205165B2 (ja) 2009-01-07
EP0898580B9 (en) 2009-08-12
US20040214765A1 (en) 2004-10-28
DE69736351T4 (de) 2009-07-23

Similar Documents

Publication Publication Date Title
ATE333465T1 (de) Methoden und mittel zur hemmung der cdk4- aktivität
Kulikov et al. Mdm2 facilitates the association of p53 with the proteasome
EP1322307A4 (en) METHOD FOR THE TREATMENT OF CELL PROLIFERATION TROUBLES AND VIRUS INFECTIONS
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
AU4073297A (en) Methods and compositions for the detection of cervical cancer
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
ATE354588T1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
WO2003029418A3 (en) Proliferation and differentiation of stem cells using extracellular matrix and other molecules
ATE552270T1 (de) Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren
EP2261667A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer
WO2003072599A3 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
WO2004069200A3 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL149416A0 (en) Human enzymes of the metalloprotease family
EP1887082A3 (en) TADG-15: An extracellular serine protease overexpressed in carcinomas
AU7525398A (en) Inhibitors for urokinase receptor
WO2004075839A3 (en) Methods and compositions for modulating apoptosis
Nikolaev et al. PARC: a potential target for cancer therapy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0898580

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
UEP Publication of translation of european patent specification

Ref document number: 0898580

Country of ref document: EP